UK markets closed
  • FTSE 100

    7,560.76
    +2.27 (+0.03%)
     
  • FTSE 250

    19,390.59
    -18.83 (-0.10%)
     
  • AIM

    854.63
    +4.07 (+0.48%)
     
  • GBP/EUR

    1.1673
    +0.0030 (+0.25%)
     
  • GBP/USD

    1.2281
    +0.0025 (+0.20%)
     
  • BTC-GBP

    13,786.72
    -116.43 (-0.84%)
     
  • CMC Crypto 200

    401.62
    +0.20 (+0.05%)
     
  • S&P 500

    4,061.77
    -14.80 (-0.36%)
     
  • DOW

    34,350.00
    -45.01 (-0.13%)
     
  • CRUDE OIL

    81.26
    +0.04 (+0.05%)
     
  • GOLD FUTURES

    1,806.20
    -9.00 (-0.50%)
     
  • NIKKEI 225

    27,777.90
    -448.18 (-1.59%)
     
  • HANG SENG

    18,675.35
    -61.09 (-0.33%)
     
  • DAX

    14,527.24
    +36.94 (+0.25%)
     
  • CAC 40

    6,741.19
    -12.78 (-0.19%)
     

Mendus AB: Mendus to participate in upcoming conferences in November

Mendus AB
Mendus AB

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:


Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Boston, MA, USA, November 8-12, 2022

Director Research Satwinder Kaur Singh and Director Business Development Céline Hechard will participate.

https://www.sitcancer.org/2022/home


Jefferies Healthcare Conference

London, UK, November 15-17, 2022

CEO Erik Manting will participate.

https://www.jefferies.com/IdeasAndPerspectives/Conferences/325/111621


Redeye Life Science Day

Stockholm, Sweden, November 24, 2022

CEO Erik Manting will participate. A pre-recorded company presentation will be made available by the conference organizer prior to the event.

https://www.redeye.se/events/850947/redeye-life-science-day


FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting

Chief Executive Officer

E-mail: ir@mendus.com


INVESTOR RELATIONS
Corey Davis

LifeSci Advisors, LLC

Telephone: + 1 212-915-2577

E-mail: cdavis@lifesciadvisors.com


MEDIA RELATIONS
Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951

E-mail: mbrkulj@valencycomms.eu


ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/

Attachment